Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 49
  • Journal CiteScore: 11.20
  • Journal Impact Factor: 8.24
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Abstract

IN-VIVO STUDIES ON THE BIOEQUIVALENCE OF SOME BRANDS OF OFLOXACIN AND LEVO-FLOXACIN TABLETS MARKETED IN NIGERIA

MR. OYIM EK, PROF. IBEZIM EC, MR. OKOYE TC, PROF. ESIMONE CO, MR. BROWN SA, MR. EKWUNIFE OI

Objective This study was aimed to assess the bioequivalence of randomly selected brands of ofloxacin and its levo-isomer, levofloxacin tablets marketed in Nigeria.

Method Bioavailability assessment was conducted by measuring the concentration of drugs in the urine and bioavailability data was presented as cumulative quantity of drugs recovered in urine in 36 hours. Microbiological assay technique was used to analyze urine samples.

Main Outcome Measure Cumulative quantity of drugs recovered in urine in 36 hours and minimum inhibitory concentrations.

Result The five brands of ofloxacin and the three brands of levofloxacin showed the same minimum inhibitory concentration value against the test strain of Staphylococcus aureus of 0.483ìg/ml and 1.953ìg/ml respectively. The result of the percentage cumulative quantity of drug recovered from urine showed that there was no statistical significant difference among ofloxacin and levofloxacin brands.

Conclusion The various brands of ofloxacin (X1 ? X5) and levofloxacin (Y1 ? Y3) in Nigeria exhibited same bioavailability data in vivo and can be said to be bioequivalents.